{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:20:45Z","timestamp":1783405245759,"version":"3.54.6"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter 2 (SGLT2) inhibitors are associated with euglycemic diabetic ketoacidosis (euDKA), typically occurring after \u22652 weeks of therapy in the setting of intercurrent illness or surgical stress. The risk of early-onset euDKA in treatment-naive patients\u2014those without prior glucose-lowering therapy or established metabolic stability\u2014remains poorly characterized. We describe a case of severe euDKA occurring within 4 days of SGLT2 inhibitor initiation, precipitated solely by metformin-induced gastrointestinal adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 40-year-old woman with newly diagnosed type 2 diabetes (HbA1c 12.9%) was initiated on metformin, henagliflozin (SGLT2 inhibitor), and chiglitazar. Within 24 hours, she developed nausea and vomiting attributed to metformin intolerance. Despite progressive symptoms and minimal oral intake over 72 hours, she continued all medications without seeking medical care. On day 4, she presented with severe high-anion-gap metabolic acidosis (pH 7.043, bicarbonate 6.5 mmol\/L), ketonemia (\u03b2-hydroxybutyrate 5.6 mmol\/L), and plasma glucose 8.5 mmol\/L\u2014consistent with euDKA. Management included intravenous dextrose, insulin infusion, and fluid resuscitation, with resolution by day 3. The patient was discharged on basal insulin, metformin, and chiglitazar (SGLT2 inhibitor discontinued), with no recurrence at 4-week follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In treatment-naive patients initiating SGLT2 inhibitor-based combination therapy, common metformin-associated gastrointestinal symptoms (10\u201330% of initiants) can precipitate severe euDKA within days through reduced oral intake and dehydration. Although these are well-recognized precipitants, this case underscores the vulnerability of treatment-naive patients to routine adverse effects during the critical initial phase, highlighting the need for stepwise drug initiation, explicit sick-day education, and scheduled early follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1882272","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:46:19Z","timestamp":1783403179000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Early-onset euglycemic diabetic ketoacidosis following henagliflozin initiation in a treatment-naive patient"],"prefix":"10.3389","volume":"17","author":[{"given":"Jing","family":"Cai","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Chengdu First People\u2019s Hospital","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Chengdu First People\u2019s Hospital","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuixia","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Chengdu First People\u2019s Hospital","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0032","article-title":"Hyperglycemic crises in adults with diabetes: a consensus report","volume":"47","author":"Umpierrez","year":"2024","journal-title":"Diabetes Care"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14788","article-title":"The management of diabetic ketoacidosis in adults: an updated guideline from the Joint British Diabetes Society for Inpatient Care","volume":"39","author":"Dhatariya","year":"2022","journal-title":"Diabetes Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41572-020-0165-1","article-title":"Diabetic ketoacidosis","volume":"6","author":"Dhatariya","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2023-003666","article-title":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","volume":"11","author":"Chow","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2024.0036","article-title":"Diabetic ketoacidosis as an effect of sodium-glucose cotransporter 2 inhibitor: real world insights","volume":"48","author":"Baek","year":"2024","journal-title":"Diabetes Metab J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14075","article-title":"Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Liu","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.09380822","article-title":"Kidney-protective effects of SGLT2 inhibitors","volume":"18","author":"Palmer","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.diabres.2017.04.004","article-title":"Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents","volume":"128","author":"Wang","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"B10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejim.2019.03.014","article-title":"Euglycemic diabetic ketoacidosis","volume":"63","author":"Barski","year":"2019","journal-title":"Eur J Intern Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v14.i8.1314","article-title":"Sodium-glucose cotransporter-2 inhibitors induced euglycemic diabetic ketoacidosis: a meta summary of case reports","volume":"14","author":"Juneja","year":"2023","journal-title":"World J Diabetes"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2025.111006","article-title":"SGLT-2 inhibitor induced euglycemic diabetes ketoacidosis in post laparoscopic distal pancreatectomy: a case report","volume":"128","author":"Chen","year":"2025","journal-title":"Int J Surg Case Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v13.i27.108550","article-title":"Euglycemic diabetic ketoacidosis associated with etogliflozin in post-pancreatitis diabetes: a case report","volume":"13","author":"Chai","year":"2025","journal-title":"World J Clin cases"},{"key":"B14","first-page":"1","article-title":"Adverse drug reaction news","volume":"26","year":"2024","journal-title":"Adverse Drug Reaction News"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v13.i3.272","article-title":"Sodium-glucose co-transporter 2 inhibitors induced euglycemic diabetic ketoacidosis within four days of initiation","volume":"13","author":"Razok","year":"2022","journal-title":"World J Diabetes"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13172245","article-title":"A novel presentation of euglycemic diabetic ketoacidosis associated with SGLT2 inhibitor and weekly GLP-1 agonist: case report","volume":"13","author":"Lyu","year":"2025","journal-title":"Healthcare (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1649270","article-title":"Severe euglycemic ketoacidosis following combined therapy with GLP-1 receptor agonist and SGLT-2 inhibitor, refractory to standard treatment: a case report","volume":"16","author":"Gandecka-Pempera","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14788","article-title":"The management of diabetic ketoacidosis in adults: an updated guideline from the Joint British Diabetes Societies for Inpatient Care","volume":"39","author":"Dhatariya","year":"2022","journal-title":"Diabetes Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12854","article-title":"Understanding and overcoming metformin gastrointestinal intolerance","volume":"19","author":"Bonnet","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00125-022-05815-1","article-title":"Ketones: the double-edged sword of SGLT2 inhibitors","volume":"66","author":"Lupsa","year":"2022","journal-title":"Diabetologia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis","volume":"38","author":"Goldenberg","year":"2016","journal-title":"Clin Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-012-0066-0","article-title":"Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia","volume":"29","author":"Haak","year":"2012","journal-title":"Adv Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.17621120","article-title":"Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy","volume":"16","author":"Palmer","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12623","article-title":"Melatonin ameliorates SGLT2 inhibitor-induced diabetic ketoacidosis by inhibiting lipolysis and hepatic ketogenesis in type 2 diabetic mice","volume":"68","author":"Park","year":"2020","journal-title":"J Pineal Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.58341","article-title":"Sodium-glucose cotransporter 2 inhibitor-induced euglycemic diabetic ketoacidosis: the other side of the coin","volume":"16","author":"Kamath","year":"2024","journal-title":"Cureus"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13415","article-title":"ISPAD Clinical Practice Consensus Guidelines 2022: Sick day management in children and adolescents with diabetes","volume":"23","author":"Phelan","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"B28","volume-title":"Type 2 Diabetes in Adults: Management. Clinical Knowledge Summary","year":"2024"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2014.02.002","article-title":"Integrated physiology and systems biology of PPARalpha","volume":"3","author":"Kersten","year":"2014","journal-title":"Mol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2021.03.019","article-title":"Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)","volume":"23","author":"Ji","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"B33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3760\/cma.j.cn115791-20241203-00705","article-title":"Guideline for the prevention and treatment of diabetes mellitus in China (2024 edition)","volume":"17","year":"2025","journal-title":"Chin J Diabetes Mellitus"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1882272\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:46:22Z","timestamp":1783403182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1882272\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":33,"alternative-id":["10.3389\/fendo.2026.1882272"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1882272","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"1882272"}}